The most commonly prescribed class of immunotherapies (called ICIs, immune checkpoint inhibitors) are not free from fulminant and fatal toxic side effects; the researchers of the Vanderbilt-Ingram Cancer Center recently evaluated their toxicities, publishing the [more]
While holidaying on the Greek island of Ithaca, where the Odyssey ended, I met a man of my age and my country who had just finished his treatment for colorectal cancer. He now lives on [more]
No cancer cell can survive, thrive, proliferate, infiltrate or metastasise without concerted help from the tumour microenvironment (TME). So shouldn’t treatment strategies aim to modify what’s happening around the cancer as much as directly targeting [more]
Game theory has been used to understand economics, ecology and evolution. It is now being used to try to help us outwit cancer. Sophie Fessl asks: will evolutionary game theory guide the way to a [more]
Whether you are a designated cancer centre leading international translational research projects, or a cancer service working to deliver high-quality treatment at a university hospital, the Organisation of European Cancer Institutes (OECI) is where you [more]
Max Rauner, Science editor at ZEIT Wissen, the popular science magazine of Germany’s largest weekly newspaper Die ZEIT, won the Cancer World Journalism Award for best article on research, with this piece on the use [more]
What does our growing understanding of the molecular subtypes of gastric and oesophageal cancers, and the results of recent trials testing multimodal therapies, mean for the way we classify, diagnose and treat these tumours? Jonas [more]
After more than ten years developing and piloting a collaborative approach to evaluating new medical technologies, EUnetHTA will come to an end in 2020. The Commission is proposing a replacement with mandatory powers, but are [more]
Health systems and insurances take decisions on reimbursing targeted medicines, doctors focus increasingly on tailoring treatments to individual patients and the molecular biology of their disease. But the need for funded quality-controlled services to do [more]
Whether the patient in front of her is old and frail, young and trying to keep their life on track, or simply struggling to come to terms with a terminal diagnosis, Helen Boyle goes the [more]
The public, politicians, and legislators debate the morals, ethics, and unintended consequences of assisted dying. But it is clinicians, in the privacy of their consulting room, who face requests to be the person giving that [more]
The recent controversy that has shaken the International Cochrane Network to its roots is very troubling. It is not yet clear if the disagreements on the quality of a recent systematic review on the efficacy [more]
Lorena Jaume-Palasí is co-founder of the NGO AlgorithmWatch, a non-profit devoted to reveal problematic Automated Decision Making (ADM) processes, algorithm biases and software failures that might have “enormous” consequences in cancer diagnosis, forecast and treatment. [more]